Hypertension in type 2 diabetes--targeting angiotensin

Area of Science:

• Endocrinology
• Nephrology
• Cardiology

Background:

• Type 2 diabetes mellitus significantly increases the risk of cardiovascular disease (CVD), accounting for approximately 60% of deaths.
• Diabetes is a primary cause of renal dysfunction and premature mortality in the UK.
• Hypertension is a prevalent comorbidity in type 2 diabetes, exacerbating vascular complications.

Purpose of the Study:

• To review the comparative advantages of angiotensin-converting enzyme (ACE) inhibitors or angiotensin-II receptor antagonists versus other antihypertensive drugs.
• To assess the impact of these specific treatments on reducing cardiovascular and renal complications in type 2 diabetes patients.

Main Methods:

• Literature review of existing studies and clinical guidelines.
• Analysis of evidence supporting the use of ACE inhibitors and angiotensin-II receptor antagonists in hypertensive patients with type 2 diabetes.

Main Results:

• Elevated blood pressure in type 2 diabetes necessitates antihypertensive treatment to mitigate vascular risks.
• National guidelines recommend ACE inhibitors or angiotensin-II receptor antagonists for selected patients.
• Evidence is reviewed to determine if these agents provide superior outcomes compared to alternative antihypertensives.

Conclusions:

• Lowering elevated blood pressure through antihypertensive therapy demonstrably reduces morbidity and mortality in type 2 diabetes.
• The review critically evaluates the specific benefits of ACE inhibitors and angiotensin-II receptor antagonists in this patient population.
• Further analysis is needed to confirm advantages over other drug classes for comprehensive risk management.